Login to Your Account


‘Urine’ trouble now: bladder bid Targacept’s next hope post-fail

By Randy Osborne
Staff Writer

Tuesday, December 17, 2013

Targacept Inc.’s Phase II blowup of TC-5619 in schizophrenia, months after its fizzle in attention deficit hyperactivity disorder (ADHD), nixed the development program and turned investor eyes to a separate therapy for overactive bladder (OAB), also in Phase II, due to report data in the middle of next year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription